People with psychotic disorders, such as schizophrenia, often experience significant difficulties in daily functioning, physical health, and quality of life. Long-acting injectable antipsychotics are an important part of treatment, but they can be associated with metabolic side effects and reduced physical fitness. Physical exercise has shown potential benefits for mental and physical health in this population; however, structured exercise programs implemented in real-world psychiatric services are still limited. The purpose of this study is to evaluate the feasibility and clinical impact of a structured, multimodal physical exercise program for adults with psychosis who are receiving long-acting injectable antipsychotic treatment. The study aims to determine whether participation in a supervised exercise program can improve physical functioning, psychological well-being, and selected biological markers related to brain health and metabolism. This study will be conducted in an outpatient psychiatric setting in Portugal and will include adults diagnosed with psychosis who are currently treated with long-acting injectable antipsychotics. Participants will be allocated to either an exercise group or a control group receiving usual care. The exercise program will last 24 weeks and will include aerobic, strength, mobility, and flexibility exercises, with supervised sessions conducted by qualified professionals. Participants will be assessed at baseline, during the intervention, after completion of the program, and at follow-up. Assessments will include measures of physical function, body composition, psychological well-being, quality of life, and blood-based biomarkers such as brain-derived neurotrophic factor, dopamine, serotonin, and metabolic indicators. The main hypothesis of this study is that individuals who participate in the physical exercise program will show improvements in physical function, mood, and overall well-being compared with those receiving usual care alone. The results of this study are expected to provide practical evidence to support the integration of structured physical exercise as an adjunct to routine psychiatric care for people with psychosis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
44
The program will be multimodal, integrating various exercise components. The aerobic component will consist of activities like walking, cycling, and circuit training. The functional strength component will include 2 to 3 exercises for the lower limbs, 2 to 3 exercises for the upper limbs, 1 to 2 exercises for the trunk and abdominal muscles, as well as 1 to 2 multi-joint exercises like burpees, swing kettlebell, among others. Lastly, the program will also incorporate mobility, balance, and flexibility exercises, such as stretching, postures, and joint mobilization.
Local Health Unit of Trás-os-Montes and Alto Douro
Vila Real, Portugal
RECRUITINGBody mass/weight
Body mass/weight measured in kilograms using a calibrated scale.
Time frame: Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up
Body mass index (BMI)
BMI calculated as weight (kg) / height (m²)
Time frame: Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up
Body fat percentage
Body fat percentage assessed by electrical bioimpedance analysis
Time frame: Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up
Lean body mass
Lean body mass (kg) assessed by electrical bioimpedance analysis
Time frame: Baseline, 12 weeks, 24 weeks, 8-week post-intervention follow-up
Sit-to-Stand Test _ 30s
Used to measure lower limb strength and endurance through the number of repetitions performed in a specific period.
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Handgrip Test
Used to assess upper limb muscle strength
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
European Health Interview Survey - Quality of Life 8-item Index (EUROHIS-QOL-8)
The European Health Interview Survey - Quality of Life 8-item Index (EUROHIS-QOL-8) is an 8-item self-report questionnaire assessing overall quality of life across physical, psychological, social, and environmental domains. Each item is rated on a 5-point Likert scale, resulting in a total score ranging from 8 to 40. Higher total scores indicate better perceived quality of life. The scale demonstrates good psychometric properties and is suitable for use in clinical and research settings.
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Patient Health Questionnaire-9 - PHQ-9
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-administered questionnaire designed to assess the severity of depressive symptoms based on the diagnostic criteria for major depressive episodes. Each item is scored on a 4-point Likert scale (0-3), yielding a total score ranging from 0 to 27. Higher total scores indicate greater severity of depressive symptoms. The PHQ-9 is widely used in clinical and research settings and demonstrates good psychometric properties.
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Positive and Negative Affect Scale (PANAS)
The Positive and Negative Affect Schedule (PANAS) is a 20-item self-report questionnaire designed to assess affective states, comprising two independent 10-item subscales: Positive Affect (PANAS-PA) and Negative Affect (PANAS-NA). Each item is rated on a 5-point Likert scale (1-5), yielding subscale scores ranging from 10 to 50. Higher scores on the Positive Affect subscale indicate higher levels of positive affect, whereas higher scores on the Negative Affect subscale indicate higher levels of negative affect. The PANAS is widely used in clinical and research settings and demonstrates good psychometric properties.
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Serum Brain-Derived Neurotrophic Factor (BDNF) levels
Serum BDNF concentration quantified using standardized Human BDNF ELISA Kit (Abcam). BDNF is a key neurotrophic marker associated with neuroplasticity and treatment-related neurobiological adaptations. Units: ng/mL.
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Serum lipid profile
Assessment of serum lipid parameters including total cholesterol, HDL cholesterol, LDL cholesterol (direct or calculated), and triglycerides, according to hospital laboratory reference standards. Units: mg/dL. Hospital laboratory references: * Total cholesterol: \< 200 mg/dL * LDL cholesterol: \< 130 mg/dL * HDL cholesterol: \> 60 mg/dL * Triglycerides: \< 150 mg/dL
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Glycemic and metabolic markers
Evaluation of fasting blood glucose and glycated hemoglobin (HbA1c) as indicators of glycemic control and metabolic health. Units: * Glucose: mg/dL * HbA1c: % Hospital reference values: * Glucose: 74-106 mg/dL * HbA1c: 4.0-6.0 %
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Serum Serotonin levels
Quantification of serotonin concentration in serum using standardized laboratory procedures. Higher or lower concentrations will be interpreted as neurochemical modulation potentially associated with the exercise intervention and antipsychotic treatment. Unit: ng/mL
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Serum Dopamine levels
Quantification of dopamine concentration in serum using standardized laboratory procedures. Changes in dopamine concentration across timepoints will be analyzed as a marker of neurochemical modulation potentially associated with the exercise intervention and antipsychotic treatment. Unit: ng/mL or pg/mL
Time frame: Baseline, 12 weeks, 24 weeks, and 8-week post-intervention follow-up
Height
Height measured in meters using stadiometer (baseline only, if applicable)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.